A study of tumor heterogeneity in a case with breast cancer.
Tumor heterogeneity has been suggested based on clinical and pathological findings. Several clinical findings can be explained by tumor evolution during progression and metastasis. We herein report a case of metastatic breast cancer indicated tumor heterogeneity by clinical findings and a genomic analysis. A 64-year-old woman with advanced breast cancer was treated with primary chemotherapy, to which primary tumor responded. After a 6 month treatment pause, lung, liver, and skin metastases developed and her serum tumor markers were elevated. None of those serum markers had been elevated before the treatment, despite the large tumor burden. Notably, there was discordance in the expression of human epidermal growth factor receptor 2 (HER2) between the primary tumor and metastatic skin lesions, with the former being negative and the latter positive. A genomic analysis was performed by in-house Breast Cancer Panel, which consisted of 53 pre-selected genes. Twenty-three somatic mutations were found in primary breast tumor and 7 in the skin metastasis. None of these 30 genes matched. However, the cell-free (cf) DNA in the plasma taken at the time of skin metastasis contained 10 mutations, 7 from the primary lesion and 3 from the metastasis. These data indicate that the clonal changes or tumor heterogeneity was shown in two solid tumors by clinical and the result of a genomic analysis. Of particular interest was that cell-free DNA could be a powerful tool to look into these dynamic changes.
Department of Breast Surgery, Yamanashi Prefectural Central Hospital, Fujimi1-1-1, Kofu, Yamanashi, Japan.
Haruka
H
Nakada
Department of Breast Surgery, Yamanashi Prefectural Central Hospital, Fujimi1-1-1, Kofu, Yamanashi, Japan. h-nakagomi@ych.pref.yamanashi.jp.
Hiroshi
H
Nakagomi
Genome Analysis Center, Yamanashi Prefectural Central Hospital, Kofu, Japan.
Yosuke
Y
Hirotsu
Genome Analysis Center, Yamanashi Prefectural Central Hospital, Kofu, Japan.
Kenji
K
Amemiya
Genome Analysis Center, Yamanashi Prefectural Central Hospital, Kofu, Japan.
Hitoshi
H
Mochizuki
Department of Breast Surgery, Yamanashi Prefectural Central Hospital, Fujimi1-1-1, Kofu, Yamanashi, Japan.
Masayuki
M
Inoue
University of Tokyo, Tokyo, Japan.
Toshio
T
Oyama
Genome Analysis Center, Yamanashi Prefectural Central Hospital, Kofu, Japan.|University of Tokyo, Tokyo, Japan.
Masao
M
Omata
D001943:Breast Neoplasms / Q000235:genetics* / Q000473:pathology* / Q000628:therapy; D005260:Female; D015972:Gene Expression Regulation, Neoplastic; D006801:Humans; D008875:Middle Aged; D009154:Mutation; D018719:Erb-b2 Receptor Tyrosine Kinases / Q000378:metabolism; D012878:Skin Neoplasms / Q000235:genetics / Q000556:secondary
D018719:Erb-b2 Receptor Tyrosine Kinases; C508053:ERBB2 protein, human
Genome analysis; Metastatic breast cancer; Tumor heterogeneity